Correlated Drug Terms (4)

---

	Name (Synonyms)	Correlation
drug1227	Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX] Wiki	1.00
drug1596	modification of the planned therapeutic management Wiki	1.00
drug1664	standard therapy Wiki	0.58
drug335	Colchicine Wiki	0.41

Correlated MeSH Terms (7)

---

	Name (Synonyms)	Correlation
D001943	Breast Neoplasms NIH	1.00
D010051	Ovarian Neoplasms NIH	1.00
D014846	Vulvar Neoplasms NIH	1.00
D002583	Uterine Cervical Neoplasms NIH	1.00
D014594	Uterine Neoplasms NIH	1.00
D014625	Vaginal Neoplasms NIH	1.00
D009369	Neoplasms, NIH	0.29

Correlated HPO Terms (7)

---

	Name (Synonyms)	Correlation
HP:0100615	Ovarian neoplasm HPO	1.00
HP:0010784	Uterine neoplasm HPO	1.00
HP:0100650	Vaginal neoplasm HPO	1.00
HP:0030416	Vulvar neoplasm HPO	1.00
HP:0030079	Cervix cancer HPO	1.00
HP:0003002	Breast carcinoma HPO	1.00
HP:0002664	Neoplasm HPO	0.30

Primary Outcomes

Description: CAS COVID 19 measures clinical and laboratory parameters in 7 domains: respiratory rate (< 18 - 0 point; 18-22 - 1 point; 23-26 - 2 point; >26 - 3 point) body temperature (35.5 - 37.0 - 0 point; < 35.5 - 1 point; 37.1 - 38.5 - 1 point; > 38.5 - 2 point) Sp02 without support oxygen (> 93% - 0 point; 90-93% - 1 point; < 90% - 2 point) ventilation (not required - 0 point; low-flow ventilation - 1 point; Non-invasive positive pressure ventilation - 2 point; mechanical ventilation - 3 point) C-reactive protein (> 10 - 0 point; 10-59 - 1 point; 60-120 - 2 point; > 120 - 3 point) d - dimer (< 0.51 - 0 point; 0.51 - 2.0 - 1 point; 2.01 - 5.0 - 2, > 5.0 - 3 point) exposure area on lung CT (no pneumonia - 0; 1-24% - 1 point; 25-50% - 2; 51-75% - 3, > 75% - 4). Minimal number of points - 0; max - 20. Lower the score-better health

Measure: change from baseline in clinical assessment score COVID 19 (CAS COVID 19) Frame: baseline

Time: baseline, day 12

---

Secondary Outcomes

Description: time to death or mechanical ventilation

Measure: Combine endpoint: Time to death or mechanical ventilation

Time: 45 days

---

Description: Change from baseline in C-reactive protein

Measure: C-reactive protein

Time: baseline, day 12, day 45

---

Description: Change from baseline in D-dimer

Measure: D-dimer

Time: baseline, day 12, day 45

---

Description: Change from baseline in EQ-5D-3L™ The EQ-5D-3L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box to the most appropriate statement. This decision results into a 1-digit number, . The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. The VAS can be used as a quantitative measure of health outcome by patient's own judgement.

Measure: EuroQol Group. EQ-5D™

Time: baseline, day 12, day 45

---

Description: Change from baseline in exposure area on lung CT

Measure: exposure area on lung CT

Time: baseline, day 12, day 45

---